SCHEMBL6791668

SCHEMBL6791668

Cc1cc(Br)ccc1C#CCCCO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PGK1 P00558 2/20 0.38
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ GABRA2 P47869 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ GABRA4 P48169 1/20 0.33
▸ GABRE P78334 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31281492 0.89 ALDH1A1 (0.41) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL20500276 0.89 ALDH1A1 (0.41) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL6304363 0.85 CYP3A4 (0.42) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL24411060 0.82 KDM4E (0.41) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL12115806 0.82 ALDH1A1 (0.47) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL6789513 0.82 FFAR1 (0.44) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL12185498 0.82 KDM4E (0.41) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL6304449 0.81 TLR8 (0.40) PYCR1
SCHEMBL7203454 0.80 RARB (0.40) ALDH1A1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL20500278 0.79 CYP1A2 (0.41) ALDH1A1KDM4ECYP1A2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784184-B2 FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES WYETH HOLDINGS CORPORATION 2004-08-31 — — US disclosed
US-6605628-B1 Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis WYETH HOLDINGS CORPORATION 2003-08-12 — — US disclosed
Send feedback